Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption by Hofmaenner, D et al.
BMJ Case Reports 2011; doi:10.1136/bcr.03.2011.3928 1 of 5
 BACKGROUND 
 Highly active antiretroviral therapy (HAART) has resulted 
in substantial decrease of HIV type-1 associated morbid-
ity and mortality. HAART is based on the prescription of 
two nucleoside analogues in concert with either a non-
nucleoside analogue or a protease inhibitor. In the current 
paradigm, HIV-infected patients need to take HAART for 
their entire life time. 
 However, the long-term use of HAART has revealed its 
downsides particularly toxicity. Some of the side effects 
associated with HAART may manifest within the fi rst 
years of intake, other side effects at later time points. 
 Didanosine (DDI), one of the fi rst nucleoside analogues, 
was introduced in the early 90s. While side effects of DDI 
such as lactate acidosis, hepatitis and polyneuropathy were 
described early after its introduction, 1  2 only recently a new 
hepatic disease in HIV-infected persons with non-cirrhotic 
portal hypertension (NCPH) has been linked to DDI. 3 – 5 
Symptoms manifest years after its intake. The syndrome 
presents mostly with the typical signs of portal hyperten-
sion, oesophageal varices, variceal bleeding, ascites and 
splenomegaly. Portal vein thrombosis is noted in many 
cases. Liver enzymes and alkaline phosphatase are often 
mildly elevated. Hepatic function is usually preserved. 5 
 The patho-mechanism of DDI causing NCPH is hypo-
thetical. DDI is a guanosine nucleoside analogue (2’,3’-dide-
oxyinosine). 2 All nucleoside analogues act similarly on HIV 
replication; they are incorporated instead of the natural 
nucleosides into the retroviral nascent DNA strand during 
reverse transcription, thereby acting as a chain terminator 
of HIV DNA. However, nucleoside analogues may also be 
incorporated into the mitochondrial DNA (mtDNA) by 
the human mitochondrial polymerase γ, this time acting 
as chain terminator of the mtDNA. Depletion of mtDNA, 
in turn, may lead to impaired mitochondrial function. This 
mitochondrial damage might injure hepatic endothelial 
cells. However, the pathogenesis of NCPH in HIV-infected 
persons is probably multifactorial. Besides DDI hyper-
coagulability has been identifi ed as an associated factor. 4 
In non-HIV-infected patients besides certain drugs, such as 
azathioprine and 6-thioguanine, autoimmune, myelopro-
liferative or lymphoproliferative diseases are associated 
with NCPH. 6 
 In this case report, we describe an HIV-positive patient 
on longstanding antiretroviral therapy presenting with 
NCPH and striking radiologic features. Even after inter-
ruption of the culprit drug, DDI, the marked radiologic 
changes persisted for more than 7 years. 
 CASE PRESENTATION 
 Herewith, we report on a homosexual 47-year-old man, 
diagnosed HIV-positive in November 1988 while present-
ing with fever and cervical lymphadenopathy. 
 In December 1992, 2×250 mg zidovudine (azidothymi-
dine (AZT))/day was started when the CD4 T cell count 
fell to 190/mm 3 ( fi gure 1A ). Because of progressive CD4 T 
cell loss, AZT was replaced by 2×200 mg DDI/day in April 
1993. Prophylaxis against pneumocystis jiroveci pneumo-
nia was installed with trimethoprim/sulfamethoxazol (160 
mg/800 mg) 3 times a week. 
 In November 1993, the patient had epigastric pain and 
elevated transaminases were measured for the fi rst time 
( fi gure 1B ). Sonographically hepatosplenomegaly without 
any sign of portal hypertension was documented. Because 
of hyperamylasemia (p-amylase 146 U/l) incriminated 
to DDI, DDI was reduced to 2×100 mg/day. Because of 
progressive CD4 T cell loss and despite manifest hepati-
tis the dose of DDI was increased to 2×200 mg/day again 
in March 1994. In January 1995, the patient presented 
with thrush stomatitis and HIV-associated thrombopenia, 
enforcing the MD in charge to add AZT 2×250 mg/day 
to DDI. Because of AZT suspected leucopenia, AZT was 
replaced by stavudine (d4T) 2×100 mg/day in November 
1995; indinavir 3×800 mg/day was added to the regimen 
in 1996 until September 1998. 
 In 1999, the patient complained of prolonged episodes of 
dysphagia, ptosis and weight loss; (body mass index 22.2 
March 1994; 18.3 kg/m 2 August 1999). Liver transaminases 
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were at that time substantially increased and ultrasound 
of the abdomen showed a pathologically hyperechogenic, 
inhomogeneous structure of the liver, irregular blood ves-
sels and retrograde portal vein fl ow, consistent with portal 
hypertension. AZT and DDI were stopped August 1999 
because of nucleoside analogues’ high likelihood to be at 
the origin of the patient’s symptoms. Subsequently, a regi-
men consisting of 600 mg efavirenz/day, 2×400 mg ritona-
vir/day, 2×400 mg saquinavir/day and 2×300 mg abacavir/
day was prescribed in September 1999. 
 Other causes of hepatopathy, such as hepatitis B and 
C infection, hemochromatosis, Wilson disease, α 1-anti-
trypsin defi ciency, autoimmune hepatitis and non-alco-
holic steatohepatitis were excluded. The patient consumed 
alcohol very rarely. 
 In August 2000, the patient suffered from episodes of 
melaena and anaemia. Endoscopy of the upper and lower 
gastrointestinal tract in November 2000 revealed oesopha-
geal varices grade I. In 2003 the patient was again hos-
pitalised due to upper gastrointestinal bleeding. Upper 
endoscopy was performed showing persistent oesopha-
geal varices grade I. CT and MRI were performed which 
demonstrated hepatosplenomegaly as signs of portal 
hypertension. In addition, several focal liver lesions were 
noted with the largest of these lesions located in liver seg-
ment IV ( fi gure 2A–D ). Histopathology of the liver showed 
a preserved architecture of the lobules, no infl ammatory 
infi ltrates or steatosis or mallory bodies ( fi gure 3 ). 
 While the incriminated drugs were stopped, transami-
nases tended to decrease over the next years ( fi gure 1B ). 
In April 2007, MRI of the liver was repeated ( fi gure 2E ). 
Although MRI revealed persistent hepatosplenomegaly and 
oesophageal varices (arrow), decrease of the liver lesion in 
liver segment IV was noted ( fi gure 2F ). Another MRI per-
formed in 2010 demonstrated near complete regression of 
the lesion ( fi gure 2G,H ). Despite the persistent prominent 
liver changes, the patient is now in good health. 
 DISCUSSION 
 In this paper we report on a 47-year-old HIV-infected man, 
developing striking imaging fi ndings of the liver suggestive 
of nodular regenerative hyperplasia (NRH) associated with 
the intake of DDI. Regression of the radiographic fi nd-
ings was very protracted with eventual disappearance 10 
years after interruption of DDI. The liver enzymes which 
were at the maximum 5–10 fold increased showed a rapid 
decrease after interruption of DDI but their normalisa-
tion is still ongoing. Clinically the patient recovered very 
quickly after stopping DDI. Thus, DDI-associated NRH 
may present with striking imaging fi ndings and the radio-
logical signs and abnormal liver enzymes may persist years 
beyond the time DDI is taken. 
 While the patient certainly benefi tted from the antiret-
roviral therapy (ART) that was started in the early 90s 
and also included DDI, he developed a myasthenia-like 
syndrome which was associated with steadily increasing 
liver enzymes over the years. These symptoms vanished 
rapidly after interruption of the ART consisting of DDI 
and d4T. DDI was the most likely culprit; indeed, long-
time exposure of DDI has recently been linked to NRH. 
Furthermore, all other conditions which are associated 
with NRH 6 were excluded. 
 NRH is one of the histological manifestations of NCPH. 
Due to vascular fl ow abnormalities, a local regenerative 
hyperplasia of hepatocytes and atrophy of the interven-
ing cells result in the characteristic nodule formation. 
Between the nodules usually there is no or little fi bro-
sis although there may be periportal or perisinusoidal 
fi brosis. Sinusoidal dilatation is often found. 6  7 It must be 
clearly distinguished from hepatitis with necrosis as well 
as from cirrhosis. Final proof for the diagnosis of NRH 
requires a liver histology. However, NRH can easily be 
missed on a liver needle biopsy in which the nodularity 
is diffi cult to appreciate. A reticulin stain can be helpful 
in demonstrating the intermixture of hypertrophic and 
atrophic areas. NRH usually becomes evident on an open 
laparoscopic biopsy allowing sampling larger pieces of 
liver tissue. 4  6 
 The imaging fi ndings in this patient over time are con-
sistent with the diagnosis of NRH associated with DDI. 
Although the regenerative nodules were visible as enhanc-
ing liver lesions on contrast-enhanced CT in this patient, 
 Figure 1  CD4 T cell counts, HIV RNA (A) and liver enzymes (B) over years in an HIV-infected patient treated with highly active antiretroviral 
treatment (HAART). ABV, abacavir; AZT, azidothymidine; DDI, didanosine (2’-3’-dideoxyinosine); d4T, stavudine (2’-3’-didehydro-2’-3’-
dideoxythymidine); EFV, efavirenz; IDV, indinavir; LPV/RTV, lopinavir/ritonavir; NLV, nelfi navir; RTV, ritonavir; SQV, saquinavir. 
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 Figure 2  (A) Contrast enhanced CT performed in 2003 demonstrates a focal liver lesion located in segment IV with contrast enhancement 
in the arterial phase of the contrast administration. In addition splenomegaly is noted as a sign of portal hypertension. (B) On a MR imaging 
performed at the same time as fi gure A the lesion is iso-slightly hypointense on T2-weighted (B) as well as hyperintense on T1-weighted 
imaging (C). Following intravenous administration of gadolinium-based contrast agent the lesion is hyperintense (D). MR imaging 4 years 
later (2007) shows that the focal liver lesion decreased in size both on unenhanced T2-weighted imaging (E) as well as on contrast-
enhanced sequences (F). MRI performed 8 years later (17 June 2010) showed that the focal liver lesion previously located in liver segment 
IV disappeared completely (G and H). However, splenomegaly as well as oesophageal varices as sign of portal hypertension remained 
unchanged. Black resp. grey arrow points to the focal lesion. Circled in red are the oesophageal varices. 
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MRI usually better displays the changes associated with 
alteration of liver structure. On T1-weighted images 
NRH nodules are hyperintense, and hypo- to isointense 
on T2-weighted images. 8 – 10 Following administration of 
intravenous contrast agents, the lesions are enhancing. 
 This case illustrates that MRI might be a useful non-
invasive examination to diagnose DDI-associated NRH. 
MRI appears to have a reasonable sensitivity of 77% and 
a specifi city of 72% in diagnosing NRH as assessed in a 
multicentre study investigating hepatic changes by liver 
biopsy and MRI in patients treated with 6-thioguanine, a 
drug well known to cause NRH. 11 
 Long-term prognosis of patients with NRH is not well 
known. It is inconclusive whether NRH is a reversible 
process once the presumed cause is removed. One report 
described an impressive reversibility of azathioprine-
induced NRH changes depicted by MRI 12 months after 
stopping the culprit drug. 12 So far, there are no long-term 
reports of HIV-infected patients with NCPH. The clini-
cal recovery of the patient described and the regression 
of radiological fi ndings while protracted are indices of a 
rather favourable prognostic. 
 In summary, here we presented a case of long-term tox-
icity of DDI causing NRH. This is the fi rst report about 
the radiologic features of DDI-associated NRH. The radio-
logic imaging and persistent elevated liver enzymes clearly 
document that the DDI associated liver changes might per-
sist more than 10 years beyond the interruption of DDI. 
Whenever liver disease is diffi cult to assign to a distinct 
pathology in HIV-infected patients, a careful drug history 
must be taken and in particular, diligence must be given 
also to drugs which have been given years before. 
 Figure 3  (A) Liver biopsy showed mostly unremarkable liver parenchyma without any signifi cant infl ammation or fi brosis (HE staining). 
(B) Reticulin staining revealed a discrete nodularity and areas with thick cords adjacent to atrophic cords. 
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 Learning points 
 ▶  DDI-associated NRH may persists years after 
interruption of DDI and must therefore be included 
in the differential diagnosis of liver diseases in HIV-
infected patients with drug history of DDI. 
 Interruption of DDI results in regression of liver fi brosis  ▶
with overall a good prognosis. 
 MRI is a useful and reasonable sensitive examination  ▶
to diagnose DDI-associated NRH. 
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